ReviewClinical optometry2025
Drug-Induced Uveitis: Patterns, Pathogenesis and Clinical Implications.
Review in Clinical optometry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Post-operative bilateral anterior uveitis: a rare case of ocular complication associated with anti-adhesion agent use in obstetric and gynaecologic surgery.Journal of surgical case reports · 2026Article
- Deep Learning-Based Quantification of Vitreous Hyperreflective Foci as a Biomarker for Intraocular Inflammation.Ophthalmology science · 2026Article
- Blood-Ocular Barrier Dysfunction in Uveitis: A Bidirectional Model Linking Pathogenesis, Clinical Monitoring, and Therapeutic Opportunities.Medical sciences (Basel, Switzerland) · 2026Review
- Clinical spectrum of intraocular inflammation following faricimab intravitreal injections: evidence from a large real-life cohort in the United Kingdom.Eye (London, England) · 2026Article
- Rates of Drug-Induced Uveitis: A Review by Medication Class.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
- Drug-induced immune-mediated uveitis: a real-world pharmacovigilance analysis using FAERS and JADER databases.BMJ open ophthalmology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-induced uveitis is a recognized but often underdiagnosed cause of ocular inflammation, with an increasing number of systemic and topical medications implicated. The clinical presentation is highly variable, ranging from anterior to posterior uveitis, often mimicking autoimmune or infectious etiologies. This review examines the mechanisms underlying drug-induced uveitis, including immune-mediated reactions, direct toxicity, and idiosyncratic responses. A comprehensive evaluation of specific drug classes is provided, covering topical agents (prostaglandin analogues, brimonidine), intravitreal therapies (anti-VEGF agents, triamcinolone and vancomycin), antimicrobials (cidofovir, rifabutin), bisphosphonates, tumor necrosis factor (TNF) inhibitors, immune checkpoint inhibitors, BRAF and MEK inhibitors, and vaccines. For each category, the review discusses the pathogenesis, frequency of occurrence, clinical presentation, diagnostic approach and management strategies. Diagnosing drug-induced uveitis requires a high index of suspicion and a systemic drug history. A structured approach to differentiating drug-induced uveitis from other inflammatory and infectious causes is outlined, emphasizing the key clinical and imaging features that aid in diagnosis. The expanding list of medications associated with uveitis underscores the need for heightened awareness in patients presenting with ocular inflammation. Establishing causality requires a careful balance of clinical pattern recognition, temporal correlation, and structured assessment tools. Understanding the pathogenesis of drug-induced uveitis not only informs treatment decisions, including whether to discontinue or modify therapy, but also helps refine guidelines for drug safety monitoring. As novel therapies, particularly in oncology, immunomodulation and vaccination, continue to evolve, ongoing research and robust pharmacovigilance efforts will be critical in identifying risks, improving diagnostic accuracy, and optimizing patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.